NCT06786026

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

QL1706 Plus Nab-paclitaxel +/- Bevacizumab As 1L Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: a Non-randomized, Multicenter Phase II Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC

Conditions

• TNBC, Triple Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	bevacizumab	bevacizumab
DRUG	QL1706	Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
DRUG	Nab paclitaxel	albumin-bound paclitaxel

Timeline

• Start date: 2024-10-09
• Primary completion: 2025-09-30
• Completion: 2028-12-31
• First posted: 2025-01-22
• Last updated: 2025-02-06

Locations

1 site across 1 country: China